Screener
Aurinia Pharmaceuticals AUPH Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $1,735 | $3,313 |
| Accrued expenses | 64,112 | 66,621 |
| Finance lease liabilities, current portion | 16,479 | 16,523 |
| Deferred revenue | 10,593 | 3,720 |
| Operating lease liabilities, current portion | 1,705 | 1,067 |
| Other current liabilities | 5,269 | 2,480 |
| Total current liabilities | 99,893 | 93,724 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's current debt?
- Aurinia Pharmaceuticals (AUPH) reported current debt of $16.48M in Q2 2026.
- How has Aurinia Pharmaceuticals's current debt changed year-over-year?
- Aurinia Pharmaceuticals's current debt increased by 1.9% year-over-year, from $16.17M to $16.48M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Aurinia Pharmaceuticals's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude